MedPath

Detour2 Continued Access Study

Not Applicable
Completed
Conditions
Peripheral Artery Diseases
Registration Number
NCT04625660
Lead Sponsor
Endologix
Brief Summary

Prospective, single-arm, multi-center, clinical investigation to continue to evaluate the safety and effectiveness of the PQ Bypass System to access, deliver guidewires, and implant stent grafts for a percutaneous femoropopliteal (fem-pop) bypass.

Detailed Description

Not available

Recruitment & Eligibility

Status
COMPLETED
Sex
All
Target Recruitment
11
Inclusion Criteria

Not provided

Exclusion Criteria

Not provided

Study & Design

Study Type
INTERVENTIONAL
Study Design
SINGLE_GROUP
Primary Outcome Measures
NameTimeMethod
Primary Safety Endpoint at 30 Days30 Days

Freedom from a major adverse event (MAE) at 30 days post-procedure defined as any occurrence of the following events: Death, Clinically-Driven Target Lesion Revascularization (CD-TLR), Major Amputation of the Treated Limb, Symptomatic Deep Vein Thrombosis (DVT), or Pulmonary Embolism, or procedure-related bleeding requiring any transfusion of packed red blood cells or surgery.

Primary Effectiveness Endpoint - Patency at 12 Months12 Months

The absence of clinically-driven target lesion revascularization and absence of recurrent target lesion diameter stenosis \>50% by imaging (e.g., duplex ultrasound peak systolic velocity ratio of \>2.5 or invasive angiography) within the stent or immediately 1 cm above or below the treated segment. When both modalities are available, angiography takes precedence.

Secondary Outcome Measures
NameTimeMethod

Trial Locations

Locations (3)

The Vascular Experts

🇺🇸

Old Saybrook, Connecticut, United States

AMITA Medical Group

🇺🇸

Elk Grove Village, Illinois, United States

Sentara Norfolk

🇺🇸

Norfolk, Virginia, United States

The Vascular Experts
🇺🇸Old Saybrook, Connecticut, United States

MedPath

Empowering clinical research with data-driven insights and AI-powered tools.

© 2025 MedPath, Inc. All rights reserved.